FindTrial
Sign In

Application research of lung cancer tumor organoids in clinical translational medicine of neoadjuvant chemotherapy combined with immunotherapy

Research on the Application of Patient-Derived Lung Cancer Organoids Models in Predicting Neoadjuvant Chemotherapy Combined with Immunotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109315
Enrollment
Unknown
Registered
2025-09-16
Start date
2025-09-20
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Observation group:Non intervention

Sponsors

Tianjin Cancer Hospital Airport Branch
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75, with no gender preference 2. Histologically or cytologically confirmed stage II-IIIA NSCLC (AJCC 8th edition) 3. Plan to receive neoadjuvant chemotherapy combined with immunotherapy and intend to undergo surgical resection 4. Sufficient tumor tissue can be obtained for organoid culture through percutaneous lung biopsy or bronchoscopy biopsy 5. ECOG performance status score of 0-1 6. Expected survival duration >= 6 months 7. Sign the informed consent form before the study

Exclusion criteria

Exclusion criteria: 1. Previously received systemic anti-tumor treatment (chemotherapy, radiotherapy, immunotherapy, etc.) 2. Accompanied by other malignant tumors or a history of malignant tumors 3. The presence of severe cardiovascular, hepatic, renal dysfunction, or immune system diseases 4. Presence of co-infection, active autoimmune disease, or immunosuppression 5. Pregnant or lactating women 6. Follow-up may not be possible during the research process.

Design outcomes

Primary

MeasureTime frame
Estimated pCR rate;—

Countries

China

Contacts

Public ContactYanjun Su

Tianjin Cancer Hospital Airport Branch 14/5000 AI Reference knowledge, personalized instructions, deep thinking, 14/5000 AI translation, AI model translation, Tianjin Cancer Hospital Airport Branch Tianjin Cancer Hospital Airport Branch

yupengfei0401@163.com+86 186 2222 1063

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026